FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
| Autor: | Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Blood. 140:526-528 |
| ISSN: | 1528-0020 0006-4971 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|